Elite Pharmaceuticals announced earlier on Thursday, that it filed an Abbreviated New Drug Application, ANDA, with the US Food and Drug Administration or an undisclosed generic drug product in a class of medications called antimetabolites. IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product.
Published first on TheFly
